Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Canexis Pharma AG is a Swiss GMP-certified manufacturer specializing in high-purity medical cannabis extracts and active pharmaceutical ingredients, including cannabidiol and dronabinol. The company has received Swissmedic approval for large-scale production, positioning itself as a key supplier for both bespoke prescription medicines and future finished pharmaceuticals. Its facility can process up to 1,000 kg of cannabis per day, producing up to 100 kg of pure product daily. The company emphasizes quality, regulatory compliance, and long-term commitment to the evolving cannabinoid-based pharmaceuticals market
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Canexis Pharma.